Pelthos Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit
| Preferred AShares | PreferredA SharesPar | PreferredC Shares | PreferredC SharesPar | CommonShares | Par | AdditionalPaid-inCapital | Accumulated Other Comprehensive Income | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2025 | 56,418 | $— | 2,600 | $— | 3,234,423 | $— | $103,675 | $— | $(64,794) | $38,881 |
| Stock-based compensation | — | — | — | — | — | — | 1,240 | — | — | 1,240 |
| Restricted stock unit expense | — | — | — | — | 15,488 | — | 668 | — | — | 668 |
| Warrants issued for venture loan and security agreement | — | — | — | — | — | — | 1,362 | — | — | 1,362 |
| Conversion of Preferred A Shares | (1,200) | — | — | — | 120,000 | — | — | — | — | — |
| Change in fair value of convertible debt due to instrument credit risk | — | — | — | — | — | — | — | 3,189 | — | 3,189 |
| Net loss | — | — | — | — | — | — | — | — | (10,238) | (10,238) |
| Balance, March 31, 2026 | 55,218 | $— | 2,600 | $— | 3,369,911 | $— | $106,945 | $3,189 | $(75,032) | $35,102 |
| Preferred AShares | PreferredA SharesPar | PreferredC Shares | PreferredC SharesPar | CommonShares | Par | AdditionalPaid-inCapital | Accumulated Other Comprehensive Income | AccumulatedDeficit | TotalStockholders’Equity (Deficit) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2024 | — | $— | 2,600 | $— | 610,389 | $— | $18,761 | $— | $(21,475) | $(2,714) |
| Stock-based compensation | — | — | — | — | — | — | 404 | — | — | 404 |
| Restricted stock unit expense | — | — | — | — | 4,635 | — | 52 | — | — | 52 |
| Shares issued for services | — | — | — | — | 1,692 | — | 30 | — | — | 30 |
| Shares issued for cash | — | — | — | — | 1,650 | — | — | — | — | — |
| Net loss | — | — | — | — | — | — | — | — | (1,968) | (1,968) |
| Balance, March 31, 2025 | — | $— | 2,600 | $— | 618,366 | $— | $19,247 | $— | $(23,443) | $(4,196) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.